An overview of the diagnostic and therapeutic use of monoclonal antibodies in medicine

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 6, 2010, Pages 574-581

  Goldsmith, S J ^a   Signore, A ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antibodies; Antibodies, monoclonal; Radioimmunodetection

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEMTUZUMAB; ARCITUMOMAB TC 99M; BASILIXIMAB; BESILESOMAB; BEVACIZUMAB; CAPROMAB PENDETIDE IN 111; CERTOLIZUMAB PEGOL; CETUXIMAB; DACLIZUMAB; EFALIZUMAB; FIBROSCINT; GENTUZUMAB; GOLIMUMAB; IBRITUMOMAB TIUXETAN; IMMUNOMODULATING AGENT; INFLIXIMAB; LEUCOSCAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; MYLOTARD; NOFETUMOMAB MERPENTAN TC 99M; OKT 3; OMALIZUMAB; ONCOSCINT; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; TOCILIZUMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ASTHMA; AUTOIMMUNE DISEASE; BONE MARROW TOXICITY; BREAST CANCER; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLEAR CELL CARCINOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG EFFICACY; GRAFT REJECTION; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOSCINTIGRAPHY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; ISOTOPE LABELING; KIDNEY CARCINOMA; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PROSTATE CARCINOMA; PSORIASIS; RADIOIMMUNOSCINTIGRAPHY; RADIOIMMUNOTHERAPY; RETINA MACULA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; THROMBUS;

ANTIBODIES, MONOCLONAL; DECISION SUPPORT TECHNIQUES; HUMANS; INFECTION; INFLAMMATION; ISOTOPE LABELING; MOLECULAR IMAGING; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 79953070535     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Berson SA, Yalow RS. Quantitative aspects of the reaction between insulin and insulin-binding antibody. J Clin Invest 1959;38:1996-2017.
2. Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, van Nagell JR Jr et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Eng J Med 1978;298:1384-7.
3. Kohler G, Milstein C. Continuous culture of fused cells secreting antibody for the detection and localization of diverse cancers by external photo scanning. N Eng J Med 1978;298:1384-6.
4. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321:522-5. (Pubitemid 16052256)
5. Lotze MT, Carrasquillo JA, Weinstein JN, Bryant GJ, Perentesis P, Reynolds JC et al. Monoclonal antibody imaging of human malignant melanoma. Ann Surg 1986;204:223-35.
6. 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest 1983;72:2101-14. (Pubitemid 14224416)
7. Vallabhajosula S. Chelation chemistry of radiometals. In: Vallabhajosula S, editor. Molecular imaging: radiopharmaceuticals for PET and SPECT. Heidelberg, London, New York: Springer;2009. p. 182-97.
8. Reddy S, Robinson MK. Immuno-positron emission tomography in cancer models. Sem Nucl Med 2010;40:182-9.
9. McCabe KE, Wu AM. Positive progress in immunoPET - not just a coincidence. Ca Biotherapy Radiopharm 2010;25 253-61.
10. Börjesson PK, Jauw YW, Boellaard R, de Bree R, Comans EF, Roos JC et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 2006;12:2133-7.
11. 64Cu-DOTA-trastuzumab. Eur J Nucl Med Mol Imaging 2009;36:1510-9.
12. 124I-cG250) and PET in patients with renal masses: A phase I trial. Lancet Oncol 2007;8:304-9.
13. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al. Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncl 2002;20:2453-63. (Pubitemid 34525730)
14. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L et al. Pivotal study of iodine I-131 tositumomab for chemotherapy-refractory low grade or transformed low grade B-cell non-Hodgkin's lymphoma. J Clin Oncol 2001;19:3918-28. (Pubitemid 32912019)
15. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H et al. Phase III trial of consolidation therapy with Yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncl 2008;26:5156-42.
16. Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR et al. Abbreviated Chemotherapy with fludarabine followed by tositumomab and iodine I-131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:5696-704.
17. 131I-tositumomabTherapy as Initial treatment for follicular lymphoma. N Eng Jour Med 2005;352:441-9. (Pubitemid 40175970)
18. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB et al. Radiolabeled antibody treatment of B-cell lymphoma with autologous bone marrow support. N Eng J Med 1993;329:1219-24. (Pubitemid 23306322)
19. Devizzi L, Guidetti A, Tarella C, Magni M, Matteucci P, Seregni E et al. High-dose Yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: An outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol 2008;26:5175-82.
20. Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D et al. Anti-prostate-specific membrane antigen-based radioimmunotherpay for prostate cancer. Cancer 2010;116:1075-1083
21. 186Re. J Nucl Med 2004;45:327-37. (Pubitemid 47618658)
22. Ugur O, Kostakoglu L, Hui ET, Fisher DR, Garmestani K, Gansow OA et al. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotheapy of neuroblastoma. Nucl Med Biol 1996;23:1-8.
23. Chatal JF, Campion L, Kraeber-Bodéré F, Bardet S, Vuillez JP, Charbonnel B et al. Survival improvement in medullary thyroid carcinoma patients who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a study by the French Tumor Endocrine Group. J Clin Oncol 2006;24:1200-7.
24. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24:823-34. (Pubitemid 46671186)
25. Signore A, Mather SJ, Piaggio G, Malviya G, Dierckx RA. Molecular imaging of inflammation/infection: nuclear medicine and optical imaging agents and methods. Chem Rev 2010;110:3112-45.
26. Malviya G, Conti F, Chianelli M, Scopinaro F, Dierckx RA, Signore A. Molecular imaging of rheumatoid arthritis by radiolabeled monoclonal antibodies: new imaging strategies to guide molecular therapies. Eur J Nucl Med Mol Imaging 2010;37:386-98.
27. Malviya G, Signore A, Laganà B, Dierckx RA. Radiolabeled peptides and monoclonal antibodies for therapy decision making in inflammatory diseases. Curr Pharm Des 2008;14:2401-14.